Esma Saâda

2.3k total citations · 1 hit paper
70 papers, 874 citations indexed

About

Esma Saâda is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Otorhinolaryngology. According to data from OpenAlex, Esma Saâda has authored 70 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 32 papers in Oncology and 23 papers in Otorhinolaryngology. Recurrent topics in Esma Saâda's work include Sarcoma Diagnosis and Treatment (24 papers), Head and Neck Cancer Studies (23 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Esma Saâda is often cited by papers focused on Sarcoma Diagnosis and Treatment (24 papers), Head and Neck Cancer Studies (23 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Esma Saâda collaborates with scholars based in France, Spain and United States. Esma Saâda's co-authors include Nicolás Isambert, Antoîne Italiano, Nicolas Penel, Jean‐Yves Blay, Sophie Piperno‐Neumann, Christine Chevreau, Elsa Kalbacher, Emmanuelle Bompas, Olivier Collard and Olivier Mir and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Esma Saâda

68 papers receiving 868 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

2018 229 citations Florence Duffaud, Olivier Mir et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Esma Saâda France	15	506	392	170	166	119	70	874
Siddhartha Laskar India	17	361 0.7×	340 0.9×	86 0.5×	185 1.1×	44 0.4×	56	818
Milan Vošmik Czechia	17	254 0.5×	258 0.7×	174 1.0×	294 1.8×	147 1.2×	81	771
Adepitan A. Owosho United States	18	713 1.4×	472 1.2×	232 1.4×	167 1.0×	138 1.2×	38	1.2k
Odd R. Monge Norway	20	746 1.5×	390 1.0×	56 0.3×	268 1.6×	139 1.2×	43	1.1k
Y.A. Abuodeh United States	13	521 1.0×	563 1.4×	143 0.8×	247 1.5×	80 0.7×	36	1.1k
Dirk Van Gestel Belgium	20	502 1.0×	439 1.1×	318 1.9×	230 1.4×	178 1.5×	88	1.2k
Handan Zeren Türkiye	14	445 0.9×	173 0.4×	42 0.2×	156 0.9×	91 0.8×	33	802
F Eschwège France	15	248 0.5×	351 0.9×	356 2.1×	323 1.9×	79 0.7×	33	882
Anna Russo Italy	18	269 0.5×	550 1.4×	89 0.5×	247 1.5×	107 0.9×	74	1.1k
İnci̇ Ayan Türkiye	15	285 0.6×	250 0.6×	172 1.0×	250 1.5×	102 0.9×	44	708

Countries citing papers authored by Esma Saâda

Since Specialization

Citations

This map shows the geographic impact of Esma Saâda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esma Saâda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esma Saâda more than expected).

Fields of papers citing papers by Esma Saâda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Esma Saâda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esma Saâda. The network helps show where Esma Saâda may publish in the future.

Co-authorship network of co-authors of Esma Saâda

This figure shows the co-authorship network connecting the top 25 collaborators of Esma Saâda. A scholar is included among the top collaborators of Esma Saâda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Esma Saâda. Esma Saâda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saâda, Esma, Jocelyn Gal, Jean‐Sébastien Frenel, et al.. (2024). 62P Phase I/II study of pazopanib and temozolomide in patients with newly diagnosed glioblastoma multiforme: PAZOGLIO trial. ESMO Open. 9. 102291–102291. 1 indexed citations

Fayette, Jérôme, Florian Clatot, Irene Braña, et al.. (2024). Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 6014–6014. 12 indexed citations

Gal, Jocelyn, Emmanuel Chamorey, Renaud Schiappa, et al.. (2023). Salvage vs. Primary Total Laryngectomy in Patients with Locally Advanced Laryngeal or Hypopharyngeal Carcinoma: Oncologic Outcomes and Their Predictive Factors. Journal of Clinical Medicine. 12(4). 1305–1305. 8 indexed citations

Gal, Jocelyn, Emmanuel Chamorey, O. Dassonville, et al.. (2023). Docetaxel-Cisplatin-Fluorouracil Induction Chemotherapy for Larynx Preservation in Patients with Locally Advanced Hypopharyngeal Cancer: Predictive Factors of Oncologic and Functional Outcomes. Journal of Clinical Medicine. 12(3). 1131–1131. 3 indexed citations

Dufresne, Armelle, Olivier Huillard, Cécile Dalban, et al.. (2022). 465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program. Annals of Oncology. 33. S753–S753. 2 indexed citations

Ambrosetti, Damien, Julien Boyer, Alexandre Bozec, et al.. (2021). The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy. Theranostics. 11(19). 9571–9586. 26 indexed citations

Crombé, Amandine, Michèle Kind, Isabelle Ray‐Coquard, et al.. (2020). Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy—A Multicenter Study by the French Sarcoma Group. American Journal of Roentgenology. 215(6). 1539–1548. 24 indexed citations

Tao, Yungan, Anne Aupérin, Xu-Shan Sun, et al.. (2020). Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). European Journal of Cancer. 141. 21–29. 58 indexed citations

Bonvalot, S., Piotr Rutkowski, Juliette Thariat, et al.. (2018). A phase II/III trial of hafnium oxide nanoparticles activated by radiotherapy in the treatment of locally advance soft tissue sarcoma of the extremity and trunk wall. Annals of Oncology. 29. viii753–viii753. 9 indexed citations

10.

Duffaud, Florence, Olivier Mir, Pascaline Boudou‐Rouquette, et al.. (2018). Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Oncology. 20(1). 120–133. 229 indexed citations breakdown →

11.

Bozec, Alexandre, Karen Bénézery, Marc Ettaiche, et al.. (2016). Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors. European Archives of Oto-Rhino-Laryngology. 273(10). 3299–3306. 13 indexed citations

12.

Bozec, Alexandre, Philippe Schultz, Jocelyn Gal, et al.. (2016). Evaluation of the information given to patients undergoing head and neck cancer surgery using the EORTC QLQ-INFO25 questionnaire: A prospective multicentric study. European Journal of Cancer. 67. 73–82. 14 indexed citations

13.

Culié, Dorian, Karen Bénézery, Emmanuel Chamorey, et al.. (2015). Salvage surgery for recurrent oropharyngeal cancer: post-operative oncologic and functional outcomes. Acta Oto-Laryngologica. 135(12). 1323–1329. 20 indexed citations

14.

Thariat, Juliette, Guillaume Vogin, V. Beckendorf, et al.. (2014). Irradiation des sarcomes cardiaques de l’adulte. Cancer/Radiothérapie. 18(2). 125–131. 7 indexed citations

15.

Bianchini, Laurence, Esma Saâda, Élodie Long-Mira, et al.. (2013). Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas. Genes Chromosomes and Cancer. 52(6). 580–590. 20 indexed citations

16.

Italiano, Antoîne, Esma Saâda, Angela Cioffi, et al.. (2012). Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. Targeted Oncology. 8(4). 295–300. 9 indexed citations

17.

Saâda, Esma, et al.. (2011). Physiopathologie et prise en charge des ascites malignes réfractaires. Bulletin du Cancer. 98(6). 679–687. 12 indexed citations

18.

Peyrade, Frédéric, Esma Saâda, Karen Bénézery, Christophe Hébert, & O. Dassonville. (2011). Chimiothérapie d’induction des carcinomes épidermoïdes de la tête et du cou. Cancer/Radiothérapie. 15(6-7). 460–465. 2 indexed citations

19.

Fernandez, Carla, Esma Saâda, Frédérique Keslair, et al.. (2009). HMGA2–NFIB fusion in a pediatric intramuscular lipoma: a novel case of NFIB alteration in a large deep-seated adipocytic tumor. Cancer Genetics and Cytogenetics. 195(1). 66–70. 24 indexed citations

20.

Saâda, Esma, Juliette Thariat, Philippe Follana, et al.. (2009). Primitive Neuroectodermal Tumor of the Pelvis in an Elderly Patient. Onkologie. 32(8). 3–3. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact